Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

EMPAGLIFLOZIN & METFORMIN

All products: general benefit

Other products in the same Health Canada class (A10B, A10BD) — coverage varies; not interchangeable

  • Dapagliflozin + metformin (Xigduo): general benefit
  • Linagliptin + metformin (Jentadueto): general benefit
  • Metformin + saxagliptin (Komboglyze): general benefit
  • Metformin + sitagliptin (Janumet XR): general benefit
  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit

12 more in the class list below

Synjardy · DIN 02456575 · 5mg & 500mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Synjardy · DIN 02456575 Manufacturer: Boehringer-Ingelheim (Canada) Ltd./Ltee; listing date 2018-10-31 Health Canada: Marketed since 2016-08-03 · brand SYNJARDY · ATC A10BD20 METFORMIN AND EMPAGLIFLOZIN, A10BD20 METFORMIN AND EMPAGLIFLOZIN · form Tablet · route Oral · ingredients METFORMIN HYDROCHLORIDE 500 MG, EMPAGLIFLOZIN 5 MG · company Boehringer ingelheim (canada) ltd ltee · schedule Prescription
Check this DIN again · Health Canada product record

Synjardy: Formulary list price $1.4535/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.4535 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94357 · Verify on the e-Formulary ↗ (DIN 02456575)

Source record
DIN 02456575: Synjardy Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002066; group id 744; item number 1818; lccId None; manufacturer id BOE Source form: Tab; strength: 5mg & 500mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $1.4535; ministry $1.4535 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456575 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94357 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: - Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR - Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following: - history of MI - multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status) - single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection - last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease - history of ischemic or hemorrhagic stroke - occlusive peripheral artery disease.
Shortage status: resolved shortage (ended 2022-06-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456575
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered

Matched class: 68:20:02 Oral Anti-Diabetic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN, SITAGLIPTIN & METFORMIN Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE, METFORMIN HCL 68:20:02 Oral Anti-Diabetic Agents

DAPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab

LINAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

SAXAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

SITAGLIPTIN & METFORMIN

· 39 products · General benefit · strengths: 50mg & 1000mg, 50mg & 500mg, 100mg & 1000mg, 50mg & 850mg · ER Tab, Tab

CANAGLIFLOZIN

· 8 products · General benefit · strengths: 100mg, 300mg · Tab

DAPAGLIFLOZIN

· 22 products · General benefit · strengths: 5mg, 10mg · Tab

EMPAGLIFLOZIN

· 2 products · General benefit · strengths: 10mg, 25mg · Tab

GLICLAZIDE

· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab

GLYBURIDE

· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab

LINAGLIPTIN

· 1 products · General benefit · strengths: 5mg · Tab

METFORMIN HCL

· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab

SAXAGLIPTIN

· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:02 and 6 more
Full class listing Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS SYNJARDY (empagliflozin and metformin hydrochloride tablets) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus inadequately controlled on: o metformin; o sulfonylurea in combination with metformin; o pioglitazone in combination with metformin; o insulin in combination with metformin; • In patients already being treated and achieving glycemic control with: o metformin and empagliflozin as separate tablets; o sulfonylurea in combination with metformin and empagliflozin as separate tablets; o pioglitazone in combination with metformin and empagliflozin as separate tablets; o insulin in combination with metformin and empagliflozin as separate tablets. Important Limitations of Use: In combination therapy, use of empagliflozin with insulin mix (regular or analogue mix) has not been studied. Therefore, SYNJARDY should not be used with insulin mix (see 14 CLINICAL TRIALS). 1.1 Pediatrics Pediatrics (<18 years of age): SYNJARDY should not be used in pediatric pati… https://pdf.hres.ca/dpd_pm/00081258.PDF PM date: JUL 29, 2016 Source product: SYNJARDY; DIN 02456575; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.